Bronchioloalveolar carcinoma with bronchorrhoea treated with erythromycin.
Recent reports have shown that erythromycin inhibits bronchial hypersecretion, and, accordingly, erythromycin was administered to a patient with bronchioloalveolar carcinoma with bronchorrhoea. After administration of erythromycin, marked reduction in the volume of sputum was observed, and the patient's quality of life was improved. It is concluded that erythromycin may reduce hypersecretion in bronchioloalveolar carcinoma.
Suga
T
T
Dept. of Pulmonary Medicine, Jichi Medical School, Tochigi, Japan.
Sugiyama
Y
Y
Fujii
T
T
Kitamura
S
S
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy / Q000503:physiopathology*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001980:Bronchi / Q000378:metabolism*; D004917:Erythromycin / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000503:physiopathology*; D008297:Male; D013183:Sputum / Q000378:metabolism*
D004917:Erythromycin